Search results
Results from the WOW.Com Content Network
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. [1] It acts against interleukin 31 (IL-31), [2] which is a cytokine involved in causing itchiness (pruritus). [2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. [3]
Y [8] rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hemolytic disease of the newborn: Adecatumumab [9] mab: human: EpCAM: prostate and breast cancer: Aducanumab [10] Aduhelm: mab: human: Amyloid beta: Y [11] Alzheimer's disease: Afasevikumab [12] mab: human ...
[7] [8] It is considered to be highly effective in dogs, and has been established as safe for at least short-term use. [ 9 ] [ 10 ] [ 11 ] Its efficacy equals that of prednisolone at first, though oclacitinib has been found to be more effective in the short term in terms of itchiness and dermatitis, long term safety is unknown. [ 12 ]
Created Date: 8/30/2012 4:52:52 PM
1.10 Platinum compounds: Carboplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Ovarian cancer, lung cancer and squamous cell head and neck cancer: Myelosuppression, nausea and vomiting (30-90%), peripheral neuropathy, ototoxicity, anaphylaxis, acute kidney failure (rare), haemolytic uraemic syndrome (rare) and loss of ...
Nearly one in three Americans over the age of 60 — roughly 19 million people — take aspirin daily, according to a 2021 study in Annals of Internal Medicine.. Should you be among that group?
76399 Ensembl ENSG00000204671 ENSMUSG00000029437 UniProt Q6EBC2 Q6EAL8 RefSeq (mRNA) NM_001014336 NM_029594 RefSeq (protein) NP_001014358 NP_083870 Location (UCSC) Chr 12: 122.17 – 122.17 Mb Chr 5: 123.62 – 123.63 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Interleukin-31 (IL-31) is a protein that in humans is encoded by the IL31 gene that resides on chromosome 12. IL-31 is ...
Non-selective CYP17A1 inhibitors that inhibit both the 17α-hydroxylase and 17,20-lyase functions must be administered alongside a glucocorticoid (e.g., prednisone) to prevent adrenal insufficiency and mineralocorticoid excess.